[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432605":3},{"organization":4,"outcomesModule":7,"designInfo":48,"detailedDescription":54,"studyPopulation":22,"armGroups":55,"interventions":75,"overallOfficials":89,"centralContacts":94,"locations":99,"responsibleParty":809,"collaborators":22,"id":811,"slug":812,"hasResults":813,"nctId":814,"briefTitle":815,"officialTitle":816,"acronym":22,"eligibilityCriteria":817,"healthyVolunteers":813,"sex":818,"minAge":819,"maxAge":22,"enrollmentInfo":820,"targetDuration":22,"studyType":823,"phases":824,"briefSummary":826,"conditions":827,"keywords":831,"overallStatus":102,"whyStopped":22,"lastUpdateSubmitDate":858,"lastUpdatePostDateStruct":859,"startDateStruct":862,"completionDateStruct":864,"leadSponsor":866,"locationsCount":867},{"fullName":5,"class":6},"Pierre Fabre Medicament","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":28,"otherOutcomes":22},[9,13,16,20,23,26],{"measure":10,"description":11,"timeFrame":12},"Part A1 Dose escalation monotherapy:","To determine the safety and tolerability of oral administration of KIN-2787 including dose-limiting toxicities (DLTs), and to identify the maximum tolerated dose (MTD) and\u002For the appropriate dose for further clinical investigation in Part B Dose Expansion.","Initiation of study drug through 28 days after last dose (up to approximately 18 months)",{"measure":14,"description":15,"timeFrame":12},"Part A2 Dose Escalation: KIN-2787 + Binimetinib Combination","To determine the safety and tolerability of oral administration of KIN-2787 + binimetinib including DLTs, and to identify the MTD and\u002For the appropriate dose for further clinical investigation.",{"measure":17,"description":18,"timeFrame":19},"In Part B (Dose Expansion) - objective response rate (ORR) using RECIST v1.1.","To assess preliminary evidence of the anti-cancer activity of KIN-2787 and for (B2) KIN-2787 + binimetinib","Initiation of study drug until disease progression (up to approximately 36 months)",{"measure":21,"description":22,"timeFrame":19},"In Part B (Dose Expansion) - disease control rate (DCR).",null,{"measure":24,"description":25,"timeFrame":19},"In Part B (Dose Expansion) - duration of overall response (DOR).","Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progression",{"measure":27,"description":22,"timeFrame":19},"In Part B (Dose Expansion) - duration of stable disease.",[29,32,34,36,38,40,42,44,46],{"measure":30,"description":22,"timeFrame":31},"Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to tmax.","Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)",{"measure":33,"description":22,"timeFrame":31},"Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to AUC.",{"measure":35,"description":22,"timeFrame":31},"Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to Cmax.",{"measure":37,"description":22,"timeFrame":31},"Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to Cmax.",{"measure":39,"description":22,"timeFrame":31},"Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to AUC.",{"measure":41,"description":22,"timeFrame":31},"Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to tmax.",{"measure":43,"description":22,"timeFrame":31},"Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to AUC.",{"measure":45,"description":22,"timeFrame":31},"Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to Cmax.",{"measure":47,"description":22,"timeFrame":31},"Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to tmax.",{"allocation":49,"interventionModel":50,"interventionModelDescription":22,"primaryPurpose":51,"observationalModel":22,"timePerspective":22,"maskingInfo":52},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":53,"maskingDescription":22,"whoMasked":22},"NONE","This is a two-part, open-label, multi-center, dose escalation and dose expansion study in participants with BRAF mutation-positive and\u002For NRAS mutation-positive tumors designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of KIN-2787, a RAF small molecule kinase inhibitor, to determine a recommended Phase 2 dose (RP2D) of KIN-2787, and to assess the objective response to KIN-2787 therapy alone and in combination with binimetinib, a mitogen-activated protein kinase (MEK) inhibitor.\n\nThe dose expansion phase (Part B) will assess the safety and efficacy of KIN-2787 at the recommended dose and schedule in patients with cancers that contain BRAF Class I, II or III mutations, including lung cancer, melanoma, and other selected solid tumors.",[56,62,67,71],{"label":57,"type":58,"description":59,"interventionNames":60},"Dose Escalation Monotherapy (Part A1)","EXPERIMENTAL","Dose escalation of KIN-2787",[61],"Drug: KIN-2787",{"label":63,"type":58,"description":64,"interventionNames":65},"Dose Escalation Combination therapy (Part A2)","Dose escalation of KIN-2787 and binimetinib",[66],"Drug: KIN-2787 and binimetinib",{"label":68,"type":58,"description":69,"interventionNames":70},"Dose Expansion Monotherapy (Part B1)","Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787",[61],{"label":72,"type":58,"description":73,"interventionNames":74},"Dose Escalation Combination therapy (Part B2)","Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 and binimetinib",[66],[76,83],{"type":77,"name":78,"description":79,"armGroupLabels":80,"otherNames":81},"DRUG","KIN-2787","KIN-2787 will be administered orally twice daily in 28-day cycles",[57,68],[82],"exarafenib",{"type":77,"name":84,"description":85,"armGroupLabels":86,"otherNames":87},"KIN-2787 and binimetinib","Continuous and Ramp-Up cohorts: KIN-2787 (exarafenib) and binimetinib will be administered orally twice daily in 28-day cycles Intermittent Cohort: KIN-2787 will be administered orally twice daily and binimetinib will be administered twice daily for 5 days on, 2 days off for 28-day cycles",[63,72],[88],"exarafenib and binimetinib",[90],{"name":91,"affiliation":92,"role":93},"Data Protection Officer","Pierre Fabre Laboratories","STUDY_CHAIR",[95],{"name":91,"role":96,"phone":97,"phoneExt":22,"email":98},"CONTACT","00 33 684752268","dpofr@pierre-fabre.com",[100,123,136,152,168,185,201,215,230,247,262,276,292,307,325,340,359,374,393,409,424,439,450,459,468,485,499,513,528,541,556,571,585,599,613,628,643,661,678,693,707,722,737,748,763,774,788,799],{"facility":101,"status":102,"city":103,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":113,"contacts":114},"The Angeles Clinic","RECRUITING","Los Angeles","California","90025-6602","United States","US",{"type":109,"coordinates":110},"Point",[111,112],-118.24368,34.05223,{"lat":112,"lon":111},[115,120],{"name":116,"role":96,"phone":117,"phoneExt":118,"email":119},"Saba Mukarram","310-231-2121","2181","smukarram@theangelesclinic.org",{"name":121,"role":122,"phone":22,"phoneExt":22,"email":22},"Omid Hamid, MD","PRINCIPAL_INVESTIGATOR",{"facility":124,"status":102,"city":103,"state":104,"zip":125,"country":106,"countryCode":107,"cosmosGeoPoint":126,"geoPoint":128,"contacts":129},"UCLA","90095",{"type":109,"coordinates":127},[111,112],{"lat":112,"lon":111},[130,134],{"name":131,"role":96,"phone":132,"phoneExt":22,"email":133},"Jessica Crocker","562-201-7669","JCrocker@mednet.ucla.edu",{"name":135,"role":122,"phone":22,"phoneExt":22,"email":22},"Bartosz Chmielowski, MD",{"facility":137,"status":102,"city":138,"state":104,"zip":139,"country":106,"countryCode":107,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"University of California San Diego, Moores Cancer Center","San Diego","92093",{"type":109,"coordinates":141},[142,143],-117.16472,32.71571,{"lat":143,"lon":142},[146,150],{"name":147,"role":96,"phone":148,"phoneExt":22,"email":149},"Nidhi Patel","1-858-822-0201","nidpatel@health.ucsd.edu",{"name":151,"role":122,"phone":22,"phoneExt":22,"email":22},"Shumei Kato, MD",{"facility":153,"status":102,"city":154,"state":104,"zip":155,"country":106,"countryCode":107,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"University of California San Francisco","San Francisco","94143-2205",{"type":109,"coordinates":157},[158,159],-122.41942,37.77493,{"lat":159,"lon":158},[162,166],{"name":163,"role":96,"phone":164,"phoneExt":22,"email":165},"Michael Wong","415-514-6714","michael.wong2@ucsf.edu",{"name":167,"role":122,"phone":22,"phoneExt":22,"email":22},"Adil Daud, MD",{"facility":169,"status":102,"city":170,"state":171,"zip":172,"country":106,"countryCode":107,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Sarah Cannon Research Institute Denver","Denver","Colorado","80218-1238",{"type":109,"coordinates":174},[175,176],-104.9847,39.73915,{"lat":176,"lon":175},[179,183],{"name":180,"role":96,"phone":181,"phoneExt":22,"email":182},"Josh Gordon","720-754-2610","Joshua.Gordon@sarahcannon.com",{"name":184,"role":122,"phone":22,"phoneExt":22,"email":22},"Ryan Weight, MD",{"facility":186,"status":102,"city":187,"state":188,"zip":189,"country":106,"countryCode":107,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Mayo Clinic - Florida","Jacksonville","Florida","32224",{"type":109,"coordinates":191},[192,193],-81.65565,30.33218,{"lat":193,"lon":192},[196,200],{"name":197,"role":96,"phone":198,"phoneExt":22,"email":199},"Ruqin Chen, MD","855-776-0015","Chen.Ruqin@mayo.edu",{"name":197,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":202,"status":102,"city":203,"state":188,"zip":204,"country":106,"countryCode":107,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Sarah Cannon Research Institute - Florida Cancer Specialists","Orlando","32827",{"type":109,"coordinates":206},[207,208],-81.37924,28.53834,{"lat":208,"lon":207},[211,213],{"name":22,"role":96,"phone":22,"phoneExt":22,"email":212},"asksarah@sarahcannon.com",{"name":214,"role":122,"phone":22,"phoneExt":22,"email":22},"Cesar Perez Batista, MD",{"facility":216,"status":102,"city":217,"state":218,"zip":219,"country":106,"countryCode":107,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"Mayo Clinic - Rochester","Rochester","Minnesota","55905",{"type":109,"coordinates":221},[222,223],-92.4699,44.02163,{"lat":223,"lon":222},[226,229],{"name":227,"role":96,"phone":198,"phoneExt":22,"email":228},"Arkadiusz Dudek, MD","Dudek.Arkadiusz@mayo.edu",{"name":227,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":231,"status":102,"city":232,"state":233,"zip":234,"country":106,"countryCode":107,"cosmosGeoPoint":235,"geoPoint":239,"contacts":240},"Atlantic Health","Morristown","New Jersey","07960",{"type":109,"coordinates":236},[237,238],-74.48154,40.79677,{"lat":238,"lon":237},[241,245],{"name":242,"role":96,"phone":243,"phoneExt":22,"email":244},"Salome Geene, RN","973-971-6373","salome.geene@atlantichealth.org",{"name":246,"role":122,"phone":22,"phoneExt":22,"email":22},"Eric Whitman, MD",{"facility":248,"status":102,"city":249,"state":233,"zip":250,"country":106,"countryCode":107,"cosmosGeoPoint":251,"geoPoint":255,"contacts":256},"Rutgers Cancer Institute of New Jersey","New Brunswick","08901",{"type":109,"coordinates":252},[253,254],-74.45182,40.48622,{"lat":254,"lon":253},[257,260],{"name":258,"role":96,"phone":22,"phoneExt":22,"email":259},"Kassie A. DiOrio","Kassie.Diorio@rutgers.edu",{"name":261,"role":122,"phone":22,"phoneExt":22,"email":22},"Sarah Weiss, MD",{"facility":263,"status":102,"city":264,"state":264,"zip":265,"country":106,"countryCode":107,"cosmosGeoPoint":266,"geoPoint":270,"contacts":271},"NYU Langone","New York","10016",{"type":109,"coordinates":267},[268,269],-74.00597,40.71427,{"lat":269,"lon":268},[272,274],{"name":273,"role":96,"phone":22,"phoneExt":22,"email":22},"CT.gov@nyulangone.org",{"name":275,"role":122,"phone":22,"phoneExt":22,"email":22},"Janice Mehnert, MD",{"facility":277,"status":102,"city":278,"state":279,"zip":280,"country":106,"countryCode":107,"cosmosGeoPoint":281,"geoPoint":285,"contacts":286},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":109,"coordinates":282},[283,284],-81.69541,41.4995,{"lat":284,"lon":283},[287,290],{"name":288,"role":96,"phone":289,"phoneExt":22,"email":22},"TaussigResearch@ccf.org","216-444-7923",{"name":291,"role":122,"phone":22,"phoneExt":22,"email":22},"Dale Shepard, MD, PhD",{"facility":293,"status":102,"city":294,"state":295,"zip":296,"country":106,"countryCode":107,"cosmosGeoPoint":297,"geoPoint":301,"contacts":302},"Sarah Cannon Research Institute-Tennessee Oncology","Nashville","Tennessee","37203",{"type":109,"coordinates":298},[299,300],-86.78444,36.16589,{"lat":300,"lon":299},[303,305],{"name":22,"role":96,"phone":304,"phoneExt":22,"email":22},"1(844) 482-4812",{"name":306,"role":122,"phone":22,"phoneExt":22,"email":22},"Meredith McKean, MD",{"facility":308,"status":309,"city":310,"state":311,"zip":312,"country":106,"countryCode":107,"cosmosGeoPoint":313,"geoPoint":317,"contacts":318},"MD Anderson","NOT_YET_RECRUITING","Houston","Texas","77030",{"type":109,"coordinates":314},[315,316],-95.36327,29.76328,{"lat":316,"lon":315},[319,323],{"name":320,"role":96,"phone":321,"phoneExt":22,"email":322},"Dahlia Mack","713-597-1352","dahmack@mdanderson.org",{"name":324,"role":122,"phone":22,"phoneExt":22,"email":22},"Hussein Tawbi, MD",{"facility":326,"status":102,"city":327,"state":328,"zip":329,"country":106,"countryCode":107,"cosmosGeoPoint":330,"geoPoint":334,"contacts":335},"Virginia Cancer Specialists","Fairfax","Virginia","22031",{"type":109,"coordinates":331},[332,333],-77.30637,38.84622,{"lat":333,"lon":332},[336],{"name":337,"role":96,"phone":338,"phoneExt":22,"email":339},"Carrie Friedman, RN, BSN, OCN","1-703-636-1473","vcsclinicaltrials@usoncology.com",{"facility":341,"status":102,"city":342,"state":343,"zip":344,"country":345,"countryCode":346,"cosmosGeoPoint":347,"geoPoint":351,"contacts":352},"Calvary Mater Hospital Newcastle","Waratah","New South Wales","2298","Australia","AU",{"type":109,"coordinates":348},[349,350],151.72647,-32.90667,{"lat":350,"lon":349},[353,357],{"name":354,"role":96,"phone":355,"phoneExt":22,"email":356},"Emily Munn","+61 (0)2 4014 3851","andre.vanderwesthuizen@calvarymater.org.au",{"name":358,"role":122,"phone":22,"phoneExt":22,"email":22},"Andre van der Westhuizen, MD",{"facility":360,"status":102,"city":361,"state":343,"zip":362,"country":345,"countryCode":346,"cosmosGeoPoint":363,"geoPoint":367,"contacts":368},"Melanoma Institute Australia","Wollstonecraft","2065",{"type":109,"coordinates":364},[365,366],151.18981,-33.8328,{"lat":366,"lon":365},[369,372],{"name":370,"role":96,"phone":371,"phoneExt":22,"email":22},"Florence Clampett","+61299117200",{"name":373,"role":122,"phone":22,"phoneExt":22,"email":22},"Georgina Long, MD",{"facility":375,"status":102,"city":376,"state":377,"zip":378,"country":345,"countryCode":346,"cosmosGeoPoint":379,"geoPoint":383,"contacts":384},"Tasman Health Care","Southport","Queensland","4215",{"type":109,"coordinates":380},[381,382],153.39796,-27.96724,{"lat":382,"lon":381},[385,389,392],{"name":386,"role":96,"phone":387,"phoneExt":22,"email":388},"Andrew Hill, MD","07 5613 2480 804","andrew.hill@tasmanhealthcare.com.au",{"name":390,"role":96,"phone":387,"phoneExt":22,"email":391},"Vishal Patel","vishal@tasmanhealthcare.com.au",{"name":386,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":394,"status":102,"city":395,"state":396,"zip":397,"country":345,"countryCode":346,"cosmosGeoPoint":398,"geoPoint":402,"contacts":403},"Austin Health","Heidelberg","Victoria","3084",{"type":109,"coordinates":399},[400,401],145.06667,-37.75,{"lat":401,"lon":400},[404,408],{"name":405,"role":96,"phone":22,"phoneExt":406,"email":407},"Damien Kee, MD","03 94965831","damien.kee@austin.org.au",{"name":405,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":410,"status":102,"city":411,"state":412,"zip":413,"country":345,"countryCode":346,"cosmosGeoPoint":414,"geoPoint":418,"contacts":419},"Linear Clinical Research","Perth","Western Australia","6009",{"type":109,"coordinates":415},[416,417],115.8614,-31.95224,{"lat":417,"lon":416},[420],{"name":421,"role":96,"phone":422,"phoneExt":22,"email":423},"Michael Millward, Professor","(08) 6382 5100","cancertrialsstartup@linear.org.au",{"facility":425,"status":102,"city":426,"state":427,"zip":428,"country":429,"countryCode":430,"cosmosGeoPoint":22,"geoPoint":22,"contacts":431},"Harbin Medical University Cancer Hospital","Haerbin","Heilongjiang","150081","China","CN",[432,434,437],{"name":22,"role":96,"phone":433,"phoneExt":22,"email":22},"+86 13845120210",{"name":435,"role":96,"phone":22,"phoneExt":22,"email":436},"Nicole Tasker","nicole@tasmanhealthcare.com.au",{"name":438,"role":122,"phone":22,"phoneExt":22,"email":22},"Yanqiao Zhang, MD",{"facility":440,"status":441,"city":442,"state":443,"zip":444,"country":429,"countryCode":430,"cosmosGeoPoint":445,"geoPoint":449,"contacts":22},"Linyi Cancer Hospital","ACTIVE_NOT_RECRUITING","Linyi","Shandong","276001",{"type":109,"coordinates":446},[447,448],118.34278,35.06306,{"lat":448,"lon":447},{"facility":451,"status":441,"city":452,"state":22,"zip":453,"country":429,"countryCode":430,"cosmosGeoPoint":454,"geoPoint":458,"contacts":22},"Beijing University Cancer Hospital","Beijing","100142",{"type":109,"coordinates":455},[456,457],116.39723,39.9075,{"lat":457,"lon":456},{"facility":460,"status":441,"city":461,"state":22,"zip":462,"country":429,"countryCode":430,"cosmosGeoPoint":463,"geoPoint":467,"contacts":22},"The Shanghai Pulmonary Hospital","Shanghai","200433",{"type":109,"coordinates":464},[465,466],121.45806,31.22222,{"lat":466,"lon":465},{"facility":469,"status":102,"city":470,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":473,"geoPoint":477,"contacts":478},"Institut Bergonie","Bordeaux","France","FR",{"type":109,"coordinates":474},[475,476],-0.58046,44.84124,{"lat":476,"lon":475},[479,483],{"name":480,"role":96,"phone":481,"phoneExt":22,"email":482},"Antonie Italiano","+33 5 47 30 60 88","a.italiano@bordeaux.unicancer.fr",{"name":484,"role":122,"phone":22,"phoneExt":22,"email":22},"Antonie Italiano, MD",{"facility":486,"status":102,"city":487,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":488,"geoPoint":492,"contacts":493},"Centre Francois Baclesse","Caen",{"type":109,"coordinates":489},[490,491],-0.35912,49.18585,{"lat":491,"lon":490},[494,498],{"name":495,"role":96,"phone":496,"phoneExt":22,"email":497},"Andreea Stefan, MD","0033 2 31 45 52 91","a.stefan@baclesse.unicancer.fr",{"name":495,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":500,"status":102,"city":501,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":502,"geoPoint":506,"contacts":507},"CHU de Lille","Lille",{"type":109,"coordinates":503},[504,505],3.05512,50.63391,{"lat":505,"lon":504},[508,512],{"name":509,"role":96,"phone":510,"phoneExt":22,"email":511},"Anthony Turpin, MD","0033 3 20 44 54 61","anthony.turpin@chu-lille.fr",{"name":509,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":514,"status":102,"city":515,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":516,"geoPoint":520,"contacts":521},"Centre Leon Berard","Lyon",{"type":109,"coordinates":517},[518,519],4.84789,45.74906,{"lat":519,"lon":518},[522,526],{"name":523,"role":96,"phone":524,"phoneExt":22,"email":525},"Philippe Cassier","+33 4 26 55 68 33","philippe.cassier@lyon.unicancer.fr",{"name":527,"role":122,"phone":22,"phoneExt":22,"email":22},"Philippe Cassier, MD",{"facility":529,"status":102,"city":530,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":531,"geoPoint":535,"contacts":536},"APHM-CHU La Timone","Marseille",{"type":109,"coordinates":532},[533,534],5.38107,43.29695,{"lat":534,"lon":533},[537],{"name":538,"role":96,"phone":539,"phoneExt":22,"email":540},"Caroline Gaudy","+33 (0) 4 91 38 75 94","mailto:caroline.gaudy@ap-hm.fr",{"facility":542,"status":102,"city":543,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":544,"geoPoint":548,"contacts":549},"CHU Nantes-Hotel Dieu","Nantes",{"type":109,"coordinates":545},[546,547],-1.55336,47.21725,{"lat":547,"lon":546},[550,554],{"name":551,"role":96,"phone":552,"phoneExt":22,"email":553},"Stephanie Bordenave","+33 2 40 16 59 30","stephanie.bordenave@chu-nantes.fr",{"name":555,"role":122,"phone":22,"phoneExt":22,"email":22},"Stephanie Bordenave, MD",{"facility":557,"status":102,"city":558,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":559,"geoPoint":563,"contacts":564},"CHU de Nice - Hôpital Archet 2","Nice",{"type":109,"coordinates":560},[561,562],7.26608,43.70313,{"lat":562,"lon":561},[565,569],{"name":566,"role":96,"phone":567,"phoneExt":22,"email":568},"Henri Montaudie, MD","0033 4 92 03 60 83","montaudie.h@chu-nice.fr",{"name":570,"role":122,"phone":22,"phoneExt":22,"email":22},"Henri Motaudie, MD",{"facility":572,"status":102,"city":573,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":574,"geoPoint":578,"contacts":579},"APHP - Hôpital St Louis","Paris",{"type":109,"coordinates":575},[576,577],2.3488,48.85341,{"lat":577,"lon":576},[580,584],{"name":581,"role":96,"phone":582,"phoneExt":22,"email":583},"Celeste Lebbe, MD","0033 1 42 49 93 92","celeste.lebbe@aphp.fr",{"name":581,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":586,"status":102,"city":587,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":588,"geoPoint":592,"contacts":593},"Hospices Civiles de Lyon - Hôpital Lyon Sud","Pierre-Bénite",{"type":109,"coordinates":589},[590,591],4.82424,45.70359,{"lat":591,"lon":590},[594,598],{"name":595,"role":96,"phone":596,"phoneExt":22,"email":597},"Stephane Dalle, MD","0033 4 78 86 16 79","stephane.dalle@chu-lyon.fr",{"name":595,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":600,"status":102,"city":601,"state":22,"zip":22,"country":471,"countryCode":472,"cosmosGeoPoint":602,"geoPoint":606,"contacts":607},"CHU de Poitiers","Poitiers",{"type":109,"coordinates":603},[604,605],0.34348,46.58261,{"lat":605,"lon":604},[608,612],{"name":609,"role":96,"phone":610,"phoneExt":22,"email":611},"Nicolas Isambert, MD","0033 5 49 44 45 48","nicolas.isambert@chu-poitiers.fr",{"name":609,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":614,"status":102,"city":615,"state":22,"zip":616,"country":471,"countryCode":472,"cosmosGeoPoint":617,"geoPoint":621,"contacts":622},"Oncopole Claudius Regaud","Toulouse","31059",{"type":109,"coordinates":618},[619,620],1.44367,43.60426,{"lat":620,"lon":619},[623,627],{"name":624,"role":96,"phone":625,"phoneExt":22,"email":626},"Cecile Pages Laurent, MD","0033 5 31 15 51 51","pageslaurent.cecile@iuct-oncopole.fr",{"name":624,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":629,"status":102,"city":630,"state":22,"zip":631,"country":471,"countryCode":472,"cosmosGeoPoint":632,"geoPoint":636,"contacts":637},"Gustave Roussy","Villejuif","94805",{"type":109,"coordinates":633},[634,635],2.35992,48.7939,{"lat":635,"lon":634},[638,642],{"name":639,"role":96,"phone":640,"phoneExt":22,"email":641},"David Planchard, MD","+ 33 (0)1 42 11 45 64","David.PLANCHARD@gustaveroussy.fr",{"name":639,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":644,"status":102,"city":645,"state":22,"zip":646,"country":647,"countryCode":648,"cosmosGeoPoint":649,"geoPoint":653,"contacts":654},"Istituto Nazionale dei Tumori Fondazione G. Pascale","Naples","80131","Italy","IT",{"type":109,"coordinates":650},[651,652],14.26811,40.85216,{"lat":652,"lon":651},[655,659],{"name":656,"role":96,"phone":657,"phoneExt":22,"email":658},"Paolo Antonio Ascierto, MD","3908117770388","p.ascierto@istitutotumori.na.it'",{"name":660,"role":122,"phone":22,"phoneExt":22,"email":22},"Paolo A Ascierto, MD",{"facility":662,"status":102,"city":663,"state":664,"zip":22,"country":664,"countryCode":665,"cosmosGeoPoint":666,"geoPoint":670,"contacts":671},"Arance","Barcelona","Spain","ES",{"type":109,"coordinates":667},[668,669],2.15899,41.38879,{"lat":669,"lon":668},[672,676],{"name":673,"role":96,"phone":674,"phoneExt":22,"email":675},"Ana Arance","+34 932275402","AMARANCE@clinic.cat",{"name":677,"role":122,"phone":22,"phoneExt":22,"email":22},"Anna Arance",{"facility":679,"status":102,"city":680,"state":664,"zip":22,"country":664,"countryCode":665,"cosmosGeoPoint":681,"geoPoint":685,"contacts":686},"NEXT Quirónsalud Madrid","Madrid",{"type":109,"coordinates":682},[683,684],-3.70256,40.4165,{"lat":684,"lon":683},[687,692],{"name":688,"role":96,"phone":689,"phoneExt":690,"email":691},"Valentina Boni, MD","(+34) 914521900","338901","vboni@nextoncology.eu",{"name":688,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":694,"status":102,"city":695,"state":664,"zip":22,"country":664,"countryCode":665,"cosmosGeoPoint":696,"geoPoint":700,"contacts":701},"H. Regional de Málaga","Málaga",{"type":109,"coordinates":697},[698,699],-4.42034,36.72016,{"lat":699,"lon":698},[702,706],{"name":703,"role":96,"phone":704,"phoneExt":22,"email":705},"Miguel A Berciano, MD","(+34) 951308129","migueberci@gmail.com",{"name":703,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":708,"status":102,"city":709,"state":664,"zip":22,"country":664,"countryCode":665,"cosmosGeoPoint":710,"geoPoint":714,"contacts":715},"H. Virgen Macarena","Seville",{"type":109,"coordinates":711},[712,713],-5.97317,37.38283,{"lat":713,"lon":712},[716,721],{"name":717,"role":96,"phone":718,"phoneExt":719,"email":720},"Luis de la Cruz","+34 629 310 196","611565","luis.cruz.sspa@juntadeandalucia.es",{"name":717,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":723,"status":102,"city":724,"state":664,"zip":22,"country":664,"countryCode":665,"cosmosGeoPoint":725,"geoPoint":729,"contacts":730},"Berrocal","Valencia",{"type":109,"coordinates":726},[727,728],-0.37966,39.47391,{"lat":728,"lon":727},[731,736],{"name":732,"role":96,"phone":733,"phoneExt":734,"email":735},"Alfonso Berrocal","+34 96.31.31.800","437635","berrocal.alf@gmail.com",{"name":732,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":738,"status":102,"city":663,"state":22,"zip":22,"country":664,"countryCode":665,"cosmosGeoPoint":739,"geoPoint":741,"contacts":742},"Hospital Quiron Dexeus",{"type":109,"coordinates":740},[668,669],{"lat":669,"lon":668},[743,747],{"name":744,"role":96,"phone":745,"phoneExt":22,"email":746},"María María González Cao, MD","+34 93 546 01 35","mgonzalezcao@oncorosell.com",{"name":744,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":749,"status":102,"city":750,"state":22,"zip":22,"country":664,"countryCode":665,"cosmosGeoPoint":751,"geoPoint":755,"contacts":756},"Hospital Universitario Insular de Gran Canaria","Las Palmas de Gran Canaria",{"type":109,"coordinates":752},[753,754],-15.41573,28.10178,{"lat":754,"lon":753},[757,761],{"name":758,"role":96,"phone":759,"phoneExt":22,"email":760},"Delvys Rodríguez","+34 928 44 17 38","drodabr@gobiernodecanarias.org",{"name":762,"role":122,"phone":22,"phoneExt":22,"email":22},"Delvys Rodríguez, MD",{"facility":764,"status":102,"city":680,"state":22,"zip":765,"country":664,"countryCode":665,"cosmosGeoPoint":766,"geoPoint":768,"contacts":769},"START Madrid","28050",{"type":109,"coordinates":767},[683,684],{"lat":684,"lon":683},[770,772],{"name":22,"role":96,"phone":771,"phoneExt":22,"email":22},"+34 917 567 825",{"name":773,"role":122,"phone":22,"phoneExt":22,"email":22},"Irene Moreno, MD",{"facility":775,"status":102,"city":680,"state":22,"zip":776,"country":664,"countryCode":665,"cosmosGeoPoint":777,"geoPoint":779,"contacts":780},"Hospital General Gregorio Marañón","29009",{"type":109,"coordinates":778},[683,684],{"lat":684,"lon":683},[781,785,787],{"name":782,"role":96,"phone":783,"phoneExt":22,"email":784},"Antonio Calles Blanco, MD","+ 34 914 26 95 16","antonio.calles@live.com",{"name":22,"role":96,"phone":786,"phoneExt":22,"email":22},"+ 34 915 86 81 15",{"name":782,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":789,"status":102,"city":724,"state":22,"zip":22,"country":664,"countryCode":665,"cosmosGeoPoint":790,"geoPoint":792,"contacts":793},"INCLIVA (Hospital Clinico de Valencia)",{"type":109,"coordinates":791},[727,728],{"lat":728,"lon":727},[794,798],{"name":795,"role":96,"phone":796,"phoneExt":22,"email":797},"Valentina Gambardella, MD","+34 961 97 35 31\u002F+34 961 97 4","valen.gambardella@gmail.com",{"name":795,"role":122,"phone":22,"phoneExt":22,"email":22},{"facility":800,"status":441,"city":801,"state":22,"zip":22,"country":802,"countryCode":803,"cosmosGeoPoint":804,"geoPoint":808,"contacts":22},"National Taiwan University Hospital","Taipei","Taiwan","TW",{"type":109,"coordinates":805},[806,807],121.52639,25.05306,{"lat":807,"lon":806},{"type":810,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100432605","phase-1-a-study-to-evaluate-kin-2787-in-participants-with-braf-andor-nras-mutation-positive-solid-tumors-100432605",false,"NCT04913285","A Study to Evaluate KIN-2787 in Participants With BRAF and\u002For NRAS Mutation Positive Solid Tumors","A Phase 1\u002F1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and\u002For NRAS Mutation-positive Solid Tumors.","Inclusion Criteria:\n\n* Provide written informed consent prior to initiation of any study-specific procedures.\n* Metastatic or advanced stage solid tumor\n* Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA.\n* Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1.\n* ECOG performance status 0-1\n* Adequate organ function, as measured by laboratory values (criteria listed in protocol).\n* Able to swallow, retain, and absorb oral medications.\n\nExclusion Criteria:\n\n* Known participants who have received local therapy with either surgery and\u002For radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria)\n* In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.\n* GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.\n* Active, uncontrolled bacterial, fungal, or viral infection.\n* Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded\n* Women who are lactating or breastfeeding, or pregnant.\n* Participants with any other active treated malignancy within 3 years prior to enrollment\n\nComplete inclusion and exclusion criteria are listed in the clinical study protocol.","ALL","18 Years",{"count":821,"type":822},400,"ESTIMATED","INTERVENTIONAL",[825],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF\u002FNRAS-mutated advanced or metastatic solid tumors.",[828,829,830],"Solid Tumor, Adult","Non-small Cell Lung Cancer","Melanoma",[832,833,834,835,836,837,838,839,840,841,842,843,844,845,846,847,848,849,850,851,852,853,854,855,856,857],"BRAF inhibitor","BRAF","pan-RAF","pan-RAF inhibitor","RAF1","ARAF","BRAF alteration","BRAF Class II","BRAF Class III","V600","tumor growth inhibitor (TGI)","melanoma","NSCLC","solid tumor","targeted therapy","BRAF Class I","NRAS","Metastatic","Unresectable","CRC","ATC","Colon","Thyroid","Advanced","Exarafenib","binimetinib","2026-08-31",{"date":860,"type":861},"2026-09-02","ACTUAL",{"date":863,"type":861},"2021-08-04",{"date":865,"type":822},"2029-03-30",{"name":5,"class":6},48]